首页> 美国卫生研究院文献>Bentham Open Access >Incorporating Natural Products Pharmaceutical Drugs Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
【2h】

Incorporating Natural Products Pharmaceutical Drugs Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases

机译:将天然产物药物自我保健和数字/移动健康技术纳入慢性疾病的分子行为联合疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Merging pharmaceutical and digital (mobile health, mHealth) ingredients to create new therapies for chronic diseases offers unique opportunities for natural products such as omega-3 polyunsaturated fatty acids (n-3 PUFA), curcumin, resveratrol, theanine, or α-lipoic acid. These compounds, when combined with pharmaceutical drugs, show improved efficacy and safety in preclinical and clinical studies of epilepsy, neuropathic pain, osteoarthritis, depression, schizophrenia, diabetes and cancer. Their additional clinical benefits include reducing levels of TNFα and other inflammatory cytokines. We describe how pleiotropic natural products can be developed as bioactive incentives within the network pharmacology together with pharmaceutical drugs and self-care interventions. Since approximately 50% of chronically-ill patients do not take pharmaceutical drugs as prescribed, psychobehavioral incentives may appeal to patients at risk for medication non-adherence. For epilepsy, the incentive-based network therapy comprises anticonvulsant drugs, antiseizure natural products (n-3 PUFA, curcumin or/and resveratrol) coupled with disease-specific behavioral interventions delivered by mobile medical apps. The add-on combination of antiseizure natural products and mHealth supports patient empowerment and intrinsic motivation by having a choice in self-care behaviors. The incentivized therapies offer opportunities: (1) to improve clinical efficacy and safety of existing drugs, (2) to catalyze patient-centered, disease self-management and behavior-changing habits, also improving health-related quality-of-life after reaching remission, and (3) merging copyrighted mHealth software with natural products, thus establishing an intellectual property protection of medical treatments comprising the natural products existing in public domain and currently promoted as dietary supplements. Taken together, clinical research on synergies between existing drugs and pleiotropic natural products, and their integration with self-care, music and mHealth, expands precision/personalized medicine strategies for chronic diseases via pharmacological-behavioral combination therapies.
机译:合并药物和数字(移动健康,mHealth)成分以创建针对慢性疾病的新疗法,为天然产品提供了独特的机会,例如omega-3多不饱和脂肪酸(n-3 PUFA),姜黄素,白藜芦醇,茶氨酸或α-硫辛酸。这些化合物与药物结合后,在癫痫,神经性疼痛,骨关节炎,抑郁症,精神分裂症,糖尿病和癌症的临床前和临床研究中显示出更高的功效和安全性。它们的其他临床益处包括降低TNFα和其他炎性细胞因子的水平。我们描述了如何在网络药理学中将多效天然产品开发为具有生物活性的诱因,以及药物和自我保健干预措施。由于大约50%的慢性病患者未按规定服用药物,因此心理行为诱因可能会吸引有药物不依从风险的患者。对于癫痫病,基于激励的网络疗法包括抗惊厥药,抗癫痫药天然产品(n-3 PUFA,姜黄素或/和白藜芦醇)以及移动医疗应用提供的针对疾病的行为干预。抗癫痫天然产品和mHealth的附加组合通过选择自我护理行为来支持患者赋权和内在动力。激励疗法提供了机会:(1)改善现有药物的临床疗效和安全性;(2)激发以患者为中心,疾病的自我管理和改变行为的习惯,还改善了达到目标后与健康相关的生活质量缓解,以及(3)将受版权保护的mHealth软件与天然产品合并,从而建立一种医学治疗的知识产权保护,其中包括在公共领域中现有的天然产品,目前已作为膳食补充剂推广。总而言之,有关现有药物与多效天然产品之间协同作用的临床研究及其与自我护理,音乐和mHealth的整合,通过药理行为组合疗法扩展了针对慢性疾病的精确/个性化药物策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号